Madrigal Pharmaceuticals sees rapid Rezdiffra sales growth with EU approval and long-term GLP-1 strategy. Learn why MDGL ...

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast may be accessed at the ...

Financial markets are inherently forward-looking, but investors who can achieve excess returns often possess a more ...

The pharmaceutical company has also earned approval for Wegovy in treating metabolic dysfunction-associated steatohepatitis ...

For years, MASH was where drug development dreams went to die.  | After Rezdiffra’s approval and Wegovy’s label expansion, ...

Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk how Rezdiffra stacks up to competitors in the MASH treatment ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On ...

Novo Nordisk saw a competitor’s bet and raised the stakes in metabolic dysfunction-associated steatohepatitis (MASH) with its planned up-to-$5.2 billion acquisition of Akero Therapeutics.

Novo Nordisk is acquiring Akero Therapeutics for drug candidate efruxifermin, which executive say could be first and best in ...

The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis.

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...